EZH2 and cancer: By conducting a structure–activity relationship study that focused on exploring various linkers, we identified MS147, which preferentially degraded PRC1 components, BMI1 and RING1B, over PRC2 components: EED, EZH2, and SUZ12, in multiple cancer cell lines.